Where does Novozymes Biopharma DK A/S rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novozymes Biopharma DK A/S ranks #32,682 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novozymes Biopharma DK A/S hold?

Novozymes Biopharma DK A/S holds 8 US utility patents granted between 2015 and 2018, spanning 8 technology areas.

What is Novozymes Biopharma DK A/S's Innovation Score?

Novozymes Biopharma DK A/S has an Innovation Score of 29.7 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novozymes Biopharma DK A/S focus on?

Novozymes Biopharma DK A/S's top technology area is C07K (Peptides) with 8 patents, ranking #1,078 of 3,615 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Novozymes Biopharma DK A/S's patent grant rate increasing or decreasing?

Novozymes Biopharma DK A/S's recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novozymes Biopharma DK A/S's patents?

Novozymes Biopharma DK A/S's patents average 20.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novozymes Biopharma DK A/S patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novozymes Biopharma DK A/S

USPTO PatentsView assignee record - 8 granted patents across 8 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novozymes ranks #32,682 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 8 technology areas.

#32,682
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.7/100): 20.1
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32682 · Foreign Corporation #32,682 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,682/49,997
PHOTO-FINISH Nouvel Heritage
CPC-NARROW C07K · 8 areas
INNOV-THIN 29.7/100
CLAIMS-DENSE 20.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nouvel Heritage (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novozymes’s 29.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (26%) Velocity 0.0 pts (0%) Breadth 10.0 pts (34%) Claim depth 12.1 pts (41%)

Qualcomm Incorporated · highest

85
Novozymes Biopharma… · this assignee

30
3D Lighting… · lowest

7

What this shows Novozymes's Innovation Score is 29.7/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novozymes?

Each dot is one of Novozymes’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novozymes’s own 20.1 claims/patent is ABOVE the 10.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Novozymes vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novozymes's grants concentrate

Novozymes Biopharma DK A/S is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (6 grants) versus a trough of 1 in 2016. By volume, Novozymes sits between Nouvel Heritage and Nrtv Collab Inc..

Nouvel Heritage

8
Nova Siri Genetic…

8
Novagen Holding

8
Novoset

8
Nproxx B V

8
NPS Pharmaceutica…

8
NRG Innovations

8
Nrtv Collab

8
Novozymes Biophar… ◀

8

What this shows Novozymes holds 8 patents at rank #32,618, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novozymes

By rank, the assignees closest to #32,618 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Novozymes's primary technology class.

Novozymes's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novozymes Biopharma DK A/S patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	75.0%
2016	1	12.5%
2018	1	12.5%

Which technologies does Novozymes Biopharma DK A/S patent most?

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

Y02A - Technologies FOR Adaptation TO Climate Change 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

B01D - Separation 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novozymes Biopharma DK A/S's patent record in context - here's where to go next.

Novozymes Biopharma DK A/S's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #32,682 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novozymes Biopharma DK A/S against Nouvel Heritage, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.